• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Vaccines to combat river blindness: expression selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model
【2h】

Vaccines to combat river blindness: expression selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model

机译：防治河盲症的疫苗：在小鼠模型中表达选择和配制抗小肠盘虫感染疫苗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human onchocerciasis is a neglected tropical disease caused by Onchocerca volvulus and an important cause of blindness and chronic disability in the developing world. Although mass drug administration of ivermectin has had a profound effect on control of the disease, additional tools are critically needed including the need for a vaccine against onchocerciasis. The objectives of the present study were to: (i) select antigens with known vaccine pedigrees as components of a vaccine; (ii) produce the selected vaccine antigens under controlled conditions, using two expression systems and in one laboratory and (iii) evaluate their vaccine efficacy using a single immunization protocol in mice. In addition, we tested the hypothesis that joining protective antigens as a fusion protein or in combination, into a multivalent vaccine, would improve the ability of the vaccine to induce protective immunity. Out of eight vaccine candidates tested in this study, Ov-103, Ov-RAL-2 and Ov-CPI-2M were shown to reproducibly induce protective immunity when administered individually, as fusion proteins or in combination. Although there was no increase in the level of protective immunity induced by combining the antigens into one vaccine, these antigens remain strong candidates for inclusion in a vaccine to control onchocerciasis in humans.
机译：人盘尾丝虫病是由盘尾丝虫（Onchocerca volvulus）引起的一种被忽视的热带病，是发展中世界失明和慢性残疾的重要原因。尽管依维菌素的大规模药物管理对控制疾病具有深远的影响，但迫切需要其他工具，包括需要抗盘尾丝虫病的疫苗。本研究的目的是：（i）选择具有已知疫苗谱系的抗原作为疫苗的成分； （ii）使用两个表达系统并在一个实验室中在受控条件下生产所选疫苗抗原，并且（iii）使用单一免疫方案在小鼠中评估其疫苗效力。此外，我们测试了以下假设：将保护性抗原作为融合蛋白或以组合形式结合到多价疫苗中，将提高疫苗诱导保护性免疫的能力。在这项研究中测试的八种候选疫苗中，Ov-103，Ov-RAL-2和Ov-CPI-2M分别以融合蛋白或组合形式给药，可再现性地诱导保护性免疫。尽管通过将抗原结合到一种疫苗中诱导的保护性免疫水平没有增加，但是这些抗原仍然是包含在控制人中盘尾丝虫病的疫苗中的强候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号